Table 1. Characteristics of study participants in the Preventing Tuberculosis Overseas Pilot Study of US immigrant visa applicants, Vietnam, 2018–2019*.
| Characteristic | No. (%) participants |
||||||
|---|---|---|---|---|---|---|---|
| Recruited | Enrolled | IGRA processed |
IGRA-positive | 3HP-eligible | Initiated 3HP | Completed 3HP | |
| Total |
5,311 |
2,438 |
2,276 |
484 |
452 |
304 |
268 |
| Sex | |||||||
| F | 2,888 (54) | 1,350 (55) | 1,304 (57) | 272 (56) | 259 (57) | 170 (56) | 152 (57) |
| M |
2,423 (46) |
1,088 (45) |
972 (43) |
212 (44) |
193 (43) |
134 (44) |
116 (43) |
| Age group, y | |||||||
| 12–14 | 298 (6) | 143 (6) | 142 (6)† | 9 (2) | 9 (2) | 4 (1) | 4 (1) |
| 15–17 | 431 (8) | 226 (9) | 223 (10) | 19 (4) | 18 (4) | 14 (5) | 13 (5) |
| 18–35 | 1,527 (29) | 773 (32) | 749 (33) | 114 (24) | 109 (24) | 69 (23) | 62 (23) |
| 36–65 | 2,909 (55) | 1,254 (51) | 1,128 (50) | 333 (69) | 307 (68) | 211 (69) | 184 (69) |
| ≥66 | 146 (3) | 42 (2) | 34 (1) | 9 (2) | 9 (2) | 6 (2) | 5 (2) |
*IGRA, interferon-γ release assay; 3HP, 3-mo regimen of isoniazid and rifapentine. †IGRA required as part of medical examination for participants 12–14 y of age; 1 participant’s IGRA was not processed for the study because of recent measles, mumps, and rubella vaccination.